No abstractBMJ. 2025 Apr 28;389:r845. doi: 10.1136/bmj.r845.NO ABSTRACTPMID:40294951 | PMC:PMC12036536 | DOI:10.1136/bmj.r845
BMJ. 2025 Mar 31;388:e082945. doi: 10.1136/bmj-2024-082945.ABSTRACTOBJECTIVES: To investigate whether a less intense antiplatelet regimen could be used for people receiving drug coated balloons.DESIGN: Multicentre, randomised, open label, assessor blind, non-inferiority trial (REC-CAGEFREE II).SETTI
BMJ. 2025 Mar 25;388:e080507. doi: 10.1136/bmj-2024-080507.ABSTRACTOBJECTIVE: To determine the effects of intensive blood pressure treatment on orthostatic hypertension.DESIGN: Systematic review and individual participant data meta-analysis.DATA SOURCES: MEDLINE, Embase, and Cochrane CENTRAL databas
BMJ. 2025 Feb 26;388:e080679. doi: 10.1136/bmj-2024-080679.ABSTRACTOBJECTIVE: To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use
No abstractBMJ. 2025 Jan 22;388:r40. doi: 10.1136/bmj.r40.NO ABSTRACTPMID:39843172 | DOI:10.1136/bmj.r40
BMJ. 2025 Jan 22;388:e081820. doi: 10.1136/bmj-2024-081820.ABSTRACTOBJECTIVE: To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.DESIGN: Multicentre, double blind, randomised, placebo controlled trial.SETTING: 16 centres in mainland China from 12 June 2020
BMJ. 2025 Jan 15;388:e082583. doi: 10.1136/bmj-2024-082583.ABSTRACTOBJECTIVE: To evaluate whether the immunomodulatory drug thymosin α1 reduces mortality in adults with sepsis.DESIGN: Multicentre, double blinded, placebo controlled phase 3 trial.SETTING: 22 centres in China, September 2016 to Decemb
BMJ. 2024 Dec 9;387:e079147. doi: 10.1136/bmj-2023-079147.ABSTRACTOBJECTIVES: To test whether haemochromatosis HFE C282Y homozygotes have increased risk of diabetes, liver disease, and heart disease even when they have normal plasma iron, transferrin saturation, or ferritin concentrations and to tes
BMJ. 2024 Dec 4;387:e078386. doi: 10.1136/bmj-2023-078386.ABSTRACTOBJECTIVE: To prospectively investigate the associations between dark, milk, and total chocolate consumption and risk of type 2 diabetes (T2D) in three US cohorts.DESIGN: Prospective cohort studies.SETTING: Nurses' Health Study (NHS;
BMJ. 2024 Nov 21;387:e081860. doi: 10.1136/bmj-2024-081860.ABSTRACTPsoriatic arthritis is an inflammatory arthritis that affects around 30% of patients with psoriasis. The disease spectrum includes peripheral arthritis, enthesitis, tenosynovitis, dactylitis, axial involvement, and skin and nail psor
No abstractBMJ. 2024 Nov 13;387:q2515. doi: 10.1136/bmj.q2515.NO ABSTRACTPMID:39537321 | DOI:10.1136/bmj.q2515
No abstractBMJ. 2024 Nov 11;387:q2471. doi: 10.1136/bmj.q2471.NO ABSTRACTPMID:39528259 | DOI:10.1136/bmj.q2471
BMJ. 2024 Nov 7;387:q2447. doi: 10.1136/bmj.q2447.ABSTRACTNew study reports protective effect among people with type 2 diabetesPMID:39510546 | PMC:PMC11541406 | DOI:10.1136/bmj.q2447
BMJ. 2024 Nov 6;387:e080925. doi: 10.1136/bmj-2024-080925.ABSTRACTOBJECTIVE: To investigate the association between sodium-glucose cotransporter-2 (SGLT-2) inhibitor use and risk of all cause mortality among patients with heart failure with reduced ejection fraction.DESIGN: Linked database study.SET
BMJ. 2024 Oct 30;387:e080035. doi: 10.1136/bmj-2024-080035.ABSTRACTOBJECTIVE: To emulate target trials comparing recurrence of nephrolithiasis among patients with pre-existing nephrolithiasis (overall and stratified by concomitant gout) initiating sodium-glucose cotransporter-2 (SGLT-2) inhibitors v
